TL;DR
An AI tool has demonstrated the ability to plan cervical cancer radiotherapy accurately in over 95% of cases in a large international trial. This development could help expand treatment access, especially in low-resource settings, supporting global cervical cancer elimination efforts.
An AI technology has demonstrated the ability to plan cervical cancer radiotherapy with high accuracy in a large international trial, supporting efforts to expand treatment access and improve outcomes globally.
The ARCHERY trial, conducted across hospitals in India, South Africa, Jordan, and Malaysia, involved over 1,000 patients with cervical, prostate, and head and neck cancers. It found that the AI software could produce radiotherapy plans meeting international standards in more than 95% of cervical cancer cases and 85% of prostate cancer cases. These results suggest the AI tool could significantly reduce planning time—down from several hours or days to just over an hour—potentially enabling more patients to receive timely treatment.
Lead researcher Professor Ajay Aggarwal of UCL and LSHTM stated that the AI’s high performance supports its routine use in hospitals worldwide, particularly in low- and middle-income countries where radiotherapy access is limited. The trial also highlights the potential for AI to bridge workforce gaps by automating complex planning tasks traditionally performed by specialists, which are often bottlenecks in resource-constrained settings.
Why It Matters
This development matters because radiotherapy is a critical component of cancer treatment, yet millions of patients lack access due to workforce shortages and equipment limitations, especially in low-income countries. By enabling faster, high-quality treatment planning, AI could help reduce cervical cancer mortality rates—particularly the 94% of deaths occurring in low- and middle-income regions—and support global initiatives aimed at eliminating cervical cancer as a public health problem.
Clinical Radiotherapy Physics with MATLAB: A Problem-Solving Approach (Series in Medical Physics and Biomedical Engineering)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Cervical cancer remains a leading cause of cancer-related death among women worldwide, with 350,000 deaths in 2022. Radiotherapy is the main curative option, but access remains limited in many low-resource settings, where only 10% of those needing treatment receive it. Previous efforts to improve access have been hampered by the complexity and time-consuming nature of treatment planning. The ARCHERY trial is among the first large-scale studies to rigorously evaluate AI’s role in this context, with prior research mostly limited to small or single-center studies, often in high-income countries.
“These results show that for cervical cancer, this AI technology achieves a very high standard, supporting its routine use in hospitals globally. It can help meet the World Health Organization’s cervical cancer elimination initiative.”
— Professor Ajay Aggarwal
“Our trial fills an important gap by rigorously testing AI technology across diverse resource settings, providing evidence needed to support widespread implementation.”
— Professor Mahesh Parmar
“Using AI to plan treatment could speed up processes, save resources, and help treat more patients, especially in lower-resource settings.”
— Professor Matthias Guckenberger
CanPlan Cancer Planner – A Planner Made for Cancer Patients and Caregivers, Best Cancer Gifts for Women and Men, Breast Cancer Gift, Cancer Journal, Undated Cancer Organizer
- Roadmap to Recovery: Based on positive psychology and neuroscience
- Holistic Healing Approach: Combines natural and conventional therapies
- Comprehensive Health Organizer: Keeps all health info in one portable binder
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
While the results are promising, it remains unclear how the AI will perform in routine clinical practice outside the trial settings, especially in facilities with limited infrastructure or less experienced staff. The long-term impact on treatment outcomes and cost-effectiveness across different health systems also requires further study.
Fairness of AI in Medical Imaging: Third International Workshop, FAIMI 2025, Held in Conjunction with MICCAI 2025, Daejeon, South Korea, September 23, … (Lecture Notes in Computer Science)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Further research will focus on evaluating AI performance in head and neck cancers, with results expected later this year. Additionally, efforts are underway to facilitate regulatory approvals, integrate AI tools into clinical workflows, and conduct implementation studies in diverse healthcare settings to confirm real-world benefits.
Pediatric Radiotherapy Planning and Treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
How does the AI tool improve radiotherapy planning?
The AI software automatically identifies tumor targets and determines optimal radiation beam configurations, reducing planning time from days or weeks to just over an hour, while maintaining high-quality standards.
Can this AI technology be used in low-resource settings?
Yes, the trial indicates the AI can produce plans meeting international standards in diverse settings, potentially helping to expand access where workforce and equipment shortages exist.
Will this AI replace human specialists?
The AI is designed to support, not replace, clinicians by automating complex planning tasks, thus freeing up specialists to focus on other aspects of patient care.
When will this AI tool be available for widespread clinical use?
Regulatory approval processes are ongoing, and further validation studies are planned to confirm performance in routine practice before widespread adoption.
What are the next steps for this research?
Researchers will evaluate the AI’s performance in head and neck cancers, conduct implementation studies, and work toward integrating the technology into standard clinical workflows globally.
